Virotherapy News and Research

RSS

Virotherapy is treatment using a virus that has been changed in the laboratory to find and destroy cancer cells without harming healthy cells. It is a type of targeted therapy. Also called oncolytic virotherapy, oncolytic virus therapy, and viral therapy.

Mayo discovery could enable development of personalized ovarian, brain cancer treatments

Mayo Clinic researchers have discovered that a molecular communication pathway – thought to be defective in cancer – is a key player in determining the effectiveness of measles virus oncolytic cancer treatment in ovarian and aggressive brain cancers.

17 May 2018

Pioneering study could be a step closer to finding the most effective way to treat cancer

Doctors could be a step closer to finding the most effective way to treat cancer with a double whammy of a virus combined with boosting the natural immune system, according to a pioneering study by researchers at The University of Texas Health Science Center at Houston (UTHealth) and The Ohio State University.

27 Apr 2018

Researchers reveal promising method for delivering cancer virotherapy

Researchers at Okayama University report in Scientific Reports a promising method for delivering viral DNA, able to eliminate cancerous cells, to a tumor. The approach, involving encapsulation of the DNA in liposomes, has the potential to enable intravenous delivery of virus-based antitumor agents.

6 Feb 2018

Scientists receive critical funding to study treatments for three deadly cancers

Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer.

17 Oct 2017

Scientists develop potential new therapy for targeting skin cancer metastases in the brain

Investigators from Brigham and Women's Hospital (BWH) and the Harvard Stem Cell Institute have a potential solution for how to kill tumor cells that have metastasized to the brain.

10 Jul 2017

Combination of immunotherapies effective against mouse model of rhabdomyosarcoma

Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually curable with traditional therapies like surgery, radiation, and chemotherapy.

20 Jun 2017

Phase 1 trial shows safety and tolerability of oncolytic HSV-1 for children, young adults with cancer

HSV1716 – an oncolytic herpes simplex virus-1 – has been studied in adults via injection into the brain and superficial tumors.

11 May 2017

IDIBELL scientists develop oncolytic virus capable of redirecting immune system to attack cancer cells

Researchers of the Cancer Virotherapy Research Group of Bellvitge Biomedicine Research Institute, led by Dr. Ramon Alemany, have developed an oncolytic virus capable of redirecting the patient's immune system against their tumor cells.

16 Feb 2017

Oncolytic virotherapy medicine shows positive treatment outcomes in late-stage cancer patients

The surprisingly positive treatment outcomes using Rigvir virotherapy for late stages cancer patients were recently published.

8 Aug 2016

Study ignores possibility that drugs, chemicals affect sexes differently

Many of the medicines we take were only ever tested on men during clinical studies. This poses a distinct danger that females are receiving suboptimal care—and that treatments specifically benefiting women are going undiscovered.

15 Jun 2016

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Oncolytic virotherapy lends benefits to melanoma patients

Recent study published online by Melanoma Research journal indicates that melanoma patients would significantly benefit from prolonging the survival with oncolytic viroherapy treatment. The study revealed that the early stage melanoma patients treated with oncolytic medicine Rigvir were 4 to 6 times more likely to survive than those who following the current guidelines for the treatment of melanoma were only observed.

19 Aug 2015

UCL research opens up new way to treat neurological disorders

The way that tetanus neurotoxin enters nerve cells has been discovered by UCL scientists, who showed that this process can be blocked, offering a potential therapeutic intervention for tetanus. This newly-discovered pathway could be exploited to deliver therapies to the nervous system, opening up a whole new way to treat neurological disorders such as motor neuron disease and peripheral neuropathies.

28 Nov 2014

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement.

26 Nov 2013

Viralytics releases financial results for 2013

Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013.

3 Sep 2013

Recombinant Newcastle disease virus kills all kinds of prostate cancer cells

A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a paper published online ahead of print in the Journal of Virology.

26 Feb 2013

Natural killer cell response detrimental to glioblastoma virotherapy

For the first time, researchers have demonstrated that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel way of treating malignant brain cancer by injecting a virus into the tumor.

5 Dec 2012

Cancer therapy with common cold virus

Common viruses have become the latest weapon against cancer. There is the case of the eight-year-old African boy diagnosed with Burkitt's lymphoma at a Ugandan health clinic. He was exposed to the measles virus and in the next few weeks his tumour regressed completely and he entered remission. But only relatively recently have scientists clinically examined the interaction between viruses and cancers in the growing area of oncolytic virotherapy.

24 Apr 2012

Advaxis, Vibalogics to develop storage-stable formulation for live Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company and Vibalogics GmbH, a German biologics manufacturing company, have agreed to co-develop a room temperature stable, processing technology for live vaccines originally engineered for Advaxis.

12 Aug 2010

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010